CN110123824B - Ilicis Pubescentis saponin A1New use of - Google Patents
Ilicis Pubescentis saponin A1New use of Download PDFInfo
- Publication number
- CN110123824B CN110123824B CN201810397921.4A CN201810397921A CN110123824B CN 110123824 B CN110123824 B CN 110123824B CN 201810397921 A CN201810397921 A CN 201810397921A CN 110123824 B CN110123824 B CN 110123824B
- Authority
- CN
- China
- Prior art keywords
- saponin
- ilexoside
- intestinal flora
- group
- hfd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 22
- 229930182490 saponin Natural products 0.000 title claims abstract description 22
- 150000007949 saponins Chemical class 0.000 title claims abstract description 22
- 230000000968 intestinal effect Effects 0.000 claims abstract description 53
- 239000003814 drug Substances 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 230000001105 regulatory effect Effects 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 9
- HFRWXKZFBNMWTN-UHFFFAOYSA-N Ilexoside D Natural products C=1C(CCC(C)C(C)=O)(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C=1C=CC2C3(C)CCC4OC1OCC(O)C(O)C1O HFRWXKZFBNMWTN-UHFFFAOYSA-N 0.000 claims description 23
- ZTSXUYAKTQNLIO-UHFFFAOYSA-N ilexoside E Natural products CC(CCC1(CCC2(C)C(=C1)C=CC3C4(C)CCC(OC5OCC(O)C(O)C5O)C(C)(C)C4CCC23C)C(=O)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6OC8OC(C)C(O)C(O)C8O)C(=O)C ZTSXUYAKTQNLIO-UHFFFAOYSA-N 0.000 claims description 23
- 229930186848 ilexoside Natural products 0.000 claims description 17
- 235000009200 high fat diet Nutrition 0.000 claims description 9
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 23
- 235000003365 Ilex pubescens Nutrition 0.000 abstract description 15
- 241001100932 Ilex pubescens Species 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 230000007413 intestinal health Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 29
- 241000894006 Bacteria Species 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- 241000192142 Proteobacteria Species 0.000 description 8
- 241000605716 Desulfovibrio Species 0.000 description 7
- 241000192125 Firmicutes Species 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 241000702460 Akkermansia Species 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000209035 Ilex Species 0.000 description 5
- AZQKTLRPVJYYOV-UHFFFAOYSA-N Ilexoside A Natural products C=1C(CCC(C)C(C)=O)(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C=1C=CC2C3(C)CCC4OC1OCC(O)C(O)C1O AZQKTLRPVJYYOV-UHFFFAOYSA-N 0.000 description 5
- FJESIUXDUUJRCG-UHFFFAOYSA-N Saponin D Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(C3C(C4C(C56CC7(C(C(CC(O7)C=C(C)C)(C)OC7C(C(O)C(O)C(C)O7)O)C6CC4)OC5)(C)CC3)(C)CC2)(C)C)OC(CO)C(O)C1O FJESIUXDUUJRCG-UHFFFAOYSA-N 0.000 description 5
- 102000003929 Transaminases Human genes 0.000 description 5
- 108090000340 Transaminases Proteins 0.000 description 5
- GKSMIYCLWJISJQ-UHFFFAOYSA-N UNPD191492 Natural products C12C(O)C(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O GKSMIYCLWJISJQ-UHFFFAOYSA-N 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000605059 Bacteroidetes Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000160321 Parabacteroides Species 0.000 description 4
- IFJUVMQPFHUIKX-UHFFFAOYSA-N Saponin D Natural products CC1CCC2(OC1)OC3CC4C5CCC6CC(CCC6(C)C5CC(=O)C4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(OC9OC(CO)C(OC%10OC(C)C(O)C(O)C%10O)C(O)C9OC%11OC(O)C(O)CC%11O)C(O)C8O)C(O)C7O IFJUVMQPFHUIKX-UHFFFAOYSA-N 0.000 description 4
- 241000123710 Sutterella Species 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 230000006020 chronic inflammation Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 235000003325 Ilex Nutrition 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000425347 Phyla <beetle> Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000252983 Caecum Species 0.000 description 2
- 241000192700 Cyanobacteria Species 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- AHPNKQUUUMEGPU-UHFFFAOYSA-N Ilexoside I Natural products CC(CCC1(CCC2(C)C(=C1)C(O)CC3C4(C)CCC(OC5OCC(O)C(O)C5OC6C(O)C(O)OC(CO)C6O)C(C)(C)C4CCC23C)C(=O)OC7OC(CO)C(O)C(O)C7O)C(=O)C AHPNKQUUUMEGPU-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241000131694 Tenericutes Species 0.000 description 2
- 241001261005 Verrucomicrobia Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241001299544 Ilex hainanensis Species 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000566145 Otus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- FWMUJAIKEJWSSY-UHFFFAOYSA-N sulfur dichloride Chemical compound ClSCl FWMUJAIKEJWSSY-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- -1 triterpenoid saponin compound Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention belongs to the technical field of medicines, and relates to pubescent holly root saponin A1The new application of the compound is pubescent holly saponin A1The application in preparing medicines and/or health products for treating or regulating intestinal flora disorder, or the application in preparing medicines and/or foods for treating or improving diseases caused by intestinal flora disorder. The compound has the advantages of pertinently changing intestinal flora, adjusting intestinal flora structure, improving intestinal health, good safety and no toxic or side effect.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a natural compound ilex pubescens saponin I lexsaponin A1The new application of (1).
Background
The intestinal flora and the host have a complex symbiotic relationship, and various metabolic pathways of the host are regulated and controlled, so that the immune-anti-inflammatory axis is influenced, and the intestinal flora participates in the physiological and biochemical activities of the host, thereby influencing the health of the host. Under normal conditions, the intestinal flora is in a dynamically balanced ecological environment. When the dietary structure of a human body is changed or the human body is infected by stress, antibiotics and exogenous pathogenic bacteria, the abnormal intestinal flora is often caused and is expressed as abnormal changes of the species, the quantity, the proportion, the positioning and the biological characteristics of the intestinal flora. Dysbacteriosis, in turn, impairs the barrier function of the intestinal tract by affecting the absorption of nutrients by the body, further aggravating the disease, thus forming a vicious circle. Research shows that imbalance of intestinal flora can cause generation of many chronic and metabolic diseases, such as diabetes, obesity, cardiovascular diseases, non-alcoholic fatty liver and the like.
Most of the existing microbial regulators are live bacteria preparations such as bifidobacterium, lactobacillus and the like, and have the problems of difficult guarantee of the number of live bacteria, poor stability and the like. Most of traditional Chinese medicines enter the digestive tract in an oral form, and macromolecular components are low in bioavailability and are retained in the intestinal tract for a long time, so that the balance of intestinal flora is influenced. Researches find that the effective components of the traditional Chinese medicine can not only support the growth of beneficial bacteria and inhibit the breeding of harmful bacteria, thereby regulating the structure of intestinal flora, but also improve the immune function of organisms, thereby achieving the purposes of adjusting yin and yang, strengthening vital qi and eliminating pathogenic factors.
Pharmacological research shows that the ilex extract generally has the functions of reducing blood fat, reducing blood pressure, resisting inflammation, protecting cardiac blood vessels and the like, and has no obvious toxic or side effect. Ilicis Pubescentis saponin A1Is a main triterpenoid saponin compound in holly plants, has the content of 4 percent in ilex hainanensis, ilex Qianguiensis, ilex trifoliata and ilex pubescens, and also has obvious functions of reducing blood fat and resisting thrombus; however, ilexoside A is not currently available1The report of the research for regulating the intestinal flora.
Disclosure of Invention
The invention aims to provide pubescent holly saponin A1The new application of the compound is that the ilexoside A1The application in preparing medicines and/or health products for treating or regulating intestinal flora disorder, or the application in preparing medicines and/or foods for treating or improving diseases caused by intestinal flora disorder.
Wherein the intestinal flora disorder is intestinal flora disorder caused by high fat diet.
The applicant observes the ilex pubescens saponin A by inducing a mouse obesity model through high-fat feed1The influence on the intestinal flora of mice is found, and the ilexoside A is discovered1Can be clearly seen (P)<0.05) changing the composition of intestinal flora, increasing the abundance of beneficial bacteria (such as Parabacteroides, Sutterella and Akkermansia), inhibiting the growth of harmful bacteria (such as Desulfovibrio), and treating or regulating intestinal flora disorder caused by high fat diet; by improving the structure of intestinal flora of mice, the composition can regulate body fat, blood sugar, transaminase and liver function caused by intestinal flora disorder caused by high-fat dietEnergy, etc.
The diseases caused by the intestinal flora disorder comprise metabolic syndromes such as diabetes, obesity, cardiovascular diseases, non-alcoholic fatty liver and the like; due to pubescent holly saponin A1Can increase the abundance of beneficial bacteria, inhibit the breeding of harmful bacteria and ensure that the intestinal flora is in a dynamic balance ecological environment, thereby ensuring the normal metabolism of the body and avoiding metabolic syndromes such as diabetes, obesity, cardiovascular diseases, non-alcoholic fatty liver and the like caused by the disturbance of the intestinal flora.
The invention relates to ilexoside A1When used in preparing medicine and/or health product for treating or regulating intestinal flora disorder, the product can enhance Ilicis Pubescentis saponin A1The medicine and/or health product is also added with ilexoside D, and ilexoside A1And ilexoside D in a weight ratio of 1-99: 1-99, by mixing pubescent holly root saponin A1The composition can be used in combination with ilexoside D to achieve better therapeutic effect.
Preferably, the pubescent holly saponin A is1And ilexoside D in a weight ratio of 2:1 or 1: 2.
the invention relates to ilexoside A1When the ilexoside I lexsaponin A is used for preparing the medicine and/or the health care product for treating or regulating the intestinal flora disorder, the ilexoside I lexsaponin A can be prepared according to a pharmaceutics method1And/or ilexoside D is prepared into a plurality of clinical drug formulations for treating or improving intestinal flora disturbance, and the oral preparation is usually selected from any one of powder, oral liquid, granules, tablets, capsules or pills.
In the present invention, ilexoside A1In the application of preparing medicines and/or foods for treating or improving diseases caused by intestinal flora disorder, the foods refer to various finished products and raw materials for human consumption or drinking, and articles which are both foods and medicines according to the tradition, but do not include articles for treatment. Specifically, the food in the invention is a substance which can be eaten or drunk by human beings, includingIndustrial, semi-finished and raw foods, including health foods, do not include tobacco or substances used only as medicines. The food in the present invention includes, but is not limited to, health food, and any food form that can be accepted by those skilled in the art is within the protection scope of the present invention, and may be one or more of solid product, dairy product, solution product, powder product or suspension product, and the present invention is not limited herein.
The invention has the advantages and beneficial effects that: the screening results of a large number of experiments show that the pubescent holly saponin A1Can pertinently change the intestinal flora, adjust the intestinal flora structure and improve the intestinal health; in addition, ilexoside A is extracted from radix Ilicis Pubescentis1After the compound is combined with the ilexoside D according to a specific proportion, the compound can better play a role in synergistically regulating the intestinal flora structure, improve the intestinal health, can be used for regulating intestinal flora disorder caused by various reasons, and has good safety and no toxic or side effect.
Drawings
FIG. 1 shows ilexoside A1And ilexoside D structure.
FIG. 2 is a mouse liver tissue morphology map.
Figure 3 is the results of mouse glucose tolerance.
Detailed Description
In order to more clearly illustrate the technical solution of the present invention, the present invention is further illustrated by the following specific examples, which are only for illustration and are not to be construed as limiting the present invention.
The applicant observes the ilex pubescens saponin A by inducing a mouse obesity model through high-fat feed1Ilexoside D and ilexoside A1The influence of the composition on the intestinal flora of mice after the composition is combined with the ilexoside D of Hainan shows that the ilexoside A1Can be clearly seen (P)<0.05) changing the composition of intestinal flora, increasing the abundance of beneficial bacteria (such as Akkermansia, Parabacteroides, Sutterella, etc.), inhibiting the growth of harmful bacteria (such as Desulfovibrio), and treating or regulating intestinal flora disorder caused by high fat diet, and ilexoside A1Used together with Ilicis Pubescentis DThe treatment effect is better; the compound can regulate body fat, blood lipid, blood sugar, transaminase and liver function caused by intestinal flora disorder due to high fat diet by improving the structure of mouse intestinal flora, and proves that pubescent holly saponin A1Can be applied to the preparation of medicines and/or health care products for treating or regulating intestinal flora disorder, or the preparation of medicines and/or foods for treating or improving diseases caused by the intestinal flora disorder.
Example 1
Ilicis Pubescentis saponin D and Ilicis Pubescentis saponin A1The preparation of (1):
soaking 5kg of folium Ilicis Hainanensis in 25L 70% methanol solution overnight, heating and reflux extracting for 1.5 hr for 2 times; mixing extractive solutions, concentrating to obtain soft extract, separating by D-101 macroporous resin adsorption, eluting with water, 50%, 70% and 95% ethanol respectively; removing tannin from 70% of the fraction by polyamide chromatographic column, concentrating the extractive solution, passing through Sephadex LH-20 gel column, collecting fraction containing saponin, mixing, and concentrating to obtain total saponin fraction; further purifying with semi-preparative liquid phase, and vacuum drying to obtain ilexoside D and ilexoside A1Monomers of ilexoside D and ilexoside A1The chemical structure of (1) is shown in figure. Ilicis Pubescentis saponin A1The detailed preparation method of the ilexoside D is disclosed in RSC adv, 2018,8, 8586-8595, and the ilexoside D can also be prepared by other conventional methods.
Example 2
The ilexoside A obtained in example 1 was added1And ilexoside D from hainan:
1. experimental animal and feed
48C 57BL/6 mice, SPF grade, 18-22g, male, supplied by Experimental animals technology, Inc., of Wei Tony Hua, Beijing; common feeds were purchased from Research Diets, usa; high fat diet (60 kal%) was manufactured by Research Diets, usa; mixing the ilexoside D with high fat feed at a ratio of 1.2g/1000g to obtain ilexoside D group feed (ilexoside D group) containing 1.2 ‰ of drug; mixing radix Ilicis Pubescentis saponin A1At a rate of 1.2g/1000gMixing the extract with high fat feed to obtain ilexoside A containing 1.2 ‰ of drug1Compound feed (pubescent holly root saponin A)1Group); mixing Ilicis Hainanensis saponin D: ilicis Pubescentis saponin A1Mixing with high fat feed at a ratio of 1:2 and a content of 1.2g/1000g to obtain composition feed containing 1.2 ‰ (composition 1 group); mixing Ilicis Hainanensis saponin D: ilicis Pubescentis saponin A1Mixing with high fat feed at a ratio of 2:1 and a content of 1.2g/1000g to obtain composition feed containing 1.2 ‰ (composition 2 group); mixing fenofibrate in an amount of 0.6g/1000g with high-fat feed to obtain composition feed (positive drug group) containing 0.6 ‰.
2. Experimental methods
2.1 Experimental animal feeding
After the tested animals enter the experimental animal center of capital medical university, 3-4 animals are put in a box at 20-25 ℃ for 12 h: 12h are lighting intermittently round the clock, freely eat and drink water, after the adaptive feeding for a week, randomly numbering the animals in groups: normal control group (Chow), model group (HFD), Hainan holly saponin D group (HFD +1.2 ‰ D), and ilexoside A1The group (HFD +1.2 thousandth A), the group 1 (HFD +1.2 thousandth C1), the group 2 (HFD +1.2 thousandth C2) and the group positive medicine (HFD +0.6 thousandth F) are given with corresponding feeds, the weight and the food intake of the mice are measured every week, the glucose tolerance of the mice in each group is measured in the 9 th week, the materials are taken in the 10 th week (the heart tip is bled, the liver, the gonad fat and the perirenal fat are taken and weighed, the caecum content is taken, and the caecum content is placed in 4 percent paraformaldehyde for fixation or is transferred and stored in a refrigerator at-80 ℃ after being frozen in liquid nitrogen according to needs).
2.2 index determination
The TC, TG, LDL-c and transaminase levels in the serum of the mice are measured by a kit method according to the instruction requirements; after paraffin embedding, H & E staining is carried out on the liver; taking mouse cecal contents, extracting total DNA of flora by using a DNA extraction kit, amplifying by using a V3-V4 region sequence of a 16S rRNA gene as a target, respectively amplifying the obtained PCR, carrying out library construction after quantitative and uniform mixing, sequencing by using an Illumina Miseq platform, carrying out OTU classification operation on the obtained optimized sequence according to 97% of similarity by using a sequencing strategy PE300, and further analyzing the abundance of the intestinal flora on each classification level.
3. Statistical analysis
All data in the experiment are expressed by mean value plus or minus standard deviation (X plus or minus s), the difference analysis among groups is carried out by adopting SPSS 19.0 software to carry out one-factor variance analysis and t test, and P is less than 0.05 and is used as the reference standard of statistical difference.
4. Results of the experiment
4.1 Effect on mouse body weight, organs and blood fat
Compared with a normal control group, the weight of the model group, the weight of the liver and the weight of adipose tissues are obviously increased (P is less than 0.01), so that the mice show an obvious obesity trend after eating high-fat feed, namely the molding is successful; compared with the model group, the weight of the positive medicine group, the weight of the two monomer groups and the weight of the composition group, the weight of the liver and the weight of adipose tissues are all reduced, and the composition has more obvious drug effect of improving the weight and the weight of visceral organs compared with the monomer. Compared with a normal control group, the levels of TC, TG and low-density cholesterol in the serum of the model group are increased, so that the blood fat content of the mouse is obviously increased after the mouse eats high-fat feed; compared with the model group, the positive medicine group, the two monomer groups and the composition group have reduced serum TC, TG and LDL levels, and the composition has more obvious effect compared with the monomer.
Table 1 mouse weight index (n ═ 8)
| Groups | Body weight (g) | Liver weight (g) | Gonadal fat (g) | Perirenal fat (g) |
| Chow | 27.99±0.70 | 1.02±0.04 | 0.45±0.03 | 0.11±0.01 |
| HFD | 45.24±1.06** | 1.45±0.07** | 2.38±0.12** | 1.02±0.04** |
| HFD+0.6‰F | 34.85±1.05## | 2.10±0.10## | 1.39±0.20## | 0.43±0.07## |
| HFD+1.2‰D | 36.93±1.04## | 1.13±0.05## | 1.87±0.19# | 0.66±0.09## |
| HFD+1.2‰A | 36.05±1.54## | 1.01±0.03## | 1.91±0.27 | 0.74±0.13# |
| HFD+1.2‰C1 | 34.53±1.26## | 1.02±0.05## | 1.40±0.23## | 0.51±0.06## |
| HFD+1.2‰C2 | 32.18±0.85## | 0.95±0.04## | 0.94±0.12## | 0.36±0.05## |
*P<0.05,**P<0.01,compared with the chow group；#P<0.05,##P<0.01,compared with the HFD group.
TABLE 2 mouse blood lipid index (n ═ 8)
| Groups | TC(mmol/L) | TG(mmol/L) | LDL-c(mmol/L) |
| Chow | 2.29±0.09 | 0.70±0.05 | 0.29±0.03 |
| HFD | 3.62±0.12** | 0.87±0.06 | 0.57±0.04** |
| HFD+0.6‰F | 3.21±0.31 | 0.32±0.04## | 0.80±0.11 |
| HFD+1.2‰D | 3.08±0.16## | 1.00±0.06 | 0.35±0.02## |
| HFD+1.2‰A | 3.03±0.13## | 0.77±0.09 | 0.36±0.04# |
| HFD+1.2‰C1 | 2.62±0.06## | 0.60±0.07# | 0.25±0.02## |
| HFD+1.2‰C2 | 3.06±0.17# | 0.55±0.06## | 0.31±0.03## |
*P<0.05,**P<0.01,compared with the chow group；#P<0.05,##P<0.01,compared with the HFD group.
4.2 Effect on liver function in mice
Compared with a normal control group, the serum AST and ALT levels of the model group are remarkably increased (P <0.05), which indicates that high fat diet causes impaired liver function; compared with the model group, the serum transaminase levels of the positive drug group, the two monomer groups and the composition group are all reduced, and the effect of the composition is more obvious compared with that of the monomer group, which shows that the composition has obvious liver protection effect, and the results are shown in table 3.
Table 3 mouse serum transaminase index (n ═ 8)
*P<0.05,**P<0.01,compared with the chow group；#P<0.05,##P<0.01,compared with the HFD group.
The morphology of mouse liver tissue is shown in fig. 2, and A in fig. 2: chow; b: HFD; c: HFD +0.6 ‰ F; d: HFD +1.2 ‰ D; e: HFD +1.2 ‰ A; f: HFD +1.2 ‰ C1; g: HFD +1.2 ‰ C2.
As can be seen from FIG. 2, the hepatocytes of the normal control group were arranged in order, the lobular structure of the liver was clear, the cells were substantially free of lipid changes, and no inflammatory cells were infiltrated in the region of the sink; the liver cells of the model group are swollen, lipid droplets with different sizes are vacuolated in the cells, the cell nucleuses are marginalized, and inflammatory cells infiltrate in a sink area, namely the obvious fatty liver; compared with a model group, each administration group has reduced adiposis and inflammatory cells, wherein ilexoside A1 has better effect of improving liver fatty lesion than ilexoside D, and the composition group has more obvious effect than a monomer group.
4.3 Effect on mouse insulin function
As shown in figure 3 glucose tolerance resultsThe fasting blood glucose value and the blood glucose peak value of the model group mouse are obviously higher than those of the normal control group, and the initial value cannot be recovered in 120min, so that the high-fat feed can cause the reduction of the sensitivity of the mouse to the pancreatic islets and the reduction of the blood glucose regulating capacity; and administering pubescent holly root saponin A1The ilexoside D can improve the sensitivity of insulin and improve the state of blood sugar intolerance, and the ilexoside A1The effect of the composition is more obvious when the composition is combined with the ilexoside D.
4.4 Effect on Chronic inflammation
Chronic inflammation is a key factor linking obesity with other diseases (type ii diabetes, atherosclerosis, fatty liver, etc.). Ilicis Pubescentis saponin A1The effect of the combination with Ilicis Hainanensis D on chronic inflammation in the body is shown in Table 4. Compared with the normal group, the level of proinflammatory factor IL-6 in the blood of the mouse in the model group and the mRNA expression quantity of liver tissues TNF-alpha, IL-1 beta and IL-6 are obviously increased, which proves that the high fat diet can cause the in vivo inflammatory reaction of the mouse; after triterpenoid saponin administration, the monomer and the composition can remarkably reduce the level of the inflammatory factor, and the ilexoside A1Has more obvious effect with the composition of the Ilicis Pubescentis saponin D.
Table 4 mouse inflammation indices (n ═ 8)
*P<0.05,**P<0.01,compared with the chow group；#P<0.05,##P<0.01,compared with the HFD group.
4.4 Effect on intestinal flora in mice
Intestinal flora sequencing revealed that the relative abundance of homologies with significant differences compared to the blank control group is shown in table 5. After species annotation, 554 OTUs were found to belong to the following phyla: firmicutes, BacteroidesPhyla (bacteroides), actinomycetes (Actinobacteria), Proteobacteria (Proteobacteria), ferrobacteria (deuterobacteria), Verrucomicrobia (Verrucomicrobia), Cyanobacteria (Cyanobacteria), Tenericutes (Tenericutes), and the like; wherein, the firmicutes, bacteroidetes and proteobacteria occupy absolute advantages in all samples, and the sum of the relative abundance of the firmicutes, the bacteroidetes and the proteobacteria is more than 90%. And according to the statistical result of the relative abundances of different phyla of bacteria of each sample, carrying out comparative analysis on the relative abundances of the above 3 phyla in each group of samples. The Firmicutes and Proteobacteria of the model groups were significantly increased and the Bacteroides was significantly decreased (P)<0.05); after administration of the composition, Bacteroidetes (bacteroides) levels increased, Firmicutes (Firmicutes) and Proteobacteria (Proteobacteria) levels decreased significantly (P)<0.05), indicating pubescent holly root saponin A1The composition and the ilexoside D have a regulating effect on high-fat feed-induced intestinal dysbacteriosis of mice, and the composition has a better effect compared with a monomer, so that the composition and the monomer have an obvious synergistic effect.
TABLE 5 Effect of groups on relative abundance of intestinal flora in mice
| Groups | Bacteroidetes(％) | Firmicutes(％) | Proteobacteria(％) |
| Chow | 32.69±6.09 | 48.99±5.21 | 6.27±1.06 |
| HFD | 13.39±3.36* | 70.91±4.09* | 16.40±0.86* |
| HFD+1.2‰D | 28.00±2.30# | 55.00±2.30# | 15.03±0.86 |
| HFD+1.2‰A | 26.00±5.10# | 56.52±2.99# | 10.92±1.46 |
| HFD+1.2‰C1 | 25.46±2.64# | 55.01±2.93# | 9.23±1.37# |
| HFD+1.2‰C2 | 24.35±2.43# | 54.35±3.01# | 10.36±0.35# |
*P<0.05,**P<0.01,compared with the chow group；#P<0.05,##P<0.01,compared with the HFD group.
The natural product has positive health effect by changing flora constitution of intestinal microorganisms (including intestinal beneficial bacteria and intestinal harmful bacteria). The effect of the triterpene saponin composition on several beneficial bacteria and harmful bacteria including intestinal tract is shown in Table 6, wherein the abundance of the genera such as Parabacteroides, Sutterella, Akkermansia and the like is increased, and the abundance of the harmful bacteria such as Desulfovibrio and the like is reduced. Desulfovibrio (Desulfovibrio) is a sulfate reducing bacterium, can metabolize sulfate to generate hydrogen sulfide, is also a gram-negative bacterium for producing LPS endotoxin, excessive chlorine sulfide can damage intestinal epithelial cells and destroy the integrity of intestinal barriers, and Lipopolysaccharide (LPS) is closely related to chronic inflammation and metabolic syndrome of organisms.
Akkermansia is a bacterium which inhabits in the crude liquid layer of the intestinal tract and can degrade mucin, and has an important promotion effect on the integrity of the intestinal barrier. The recent research shows that the bacterium can improve the metabolic disorder conditions of the obese mice without changing the diet, including fat mass reduction, endotoxin metabolism, adipose tissue inflammation improvement, insulin resistance improvement and the like. Compared with a normal control group, the high-fat diet can reduce the number of intestinal probiotics of mice, Akkermansia can hardly detect the intestinal probiotics, and the number of vibrio desulfovibrio is increased. Compared with a model control group, the triterpene saponin composition can improve the abundance of beneficial bacteria and reduce the abundance of harmful bacteria.
Table 6 effect of groups on relative abundance of beneficial and harmful bacteria in several common intestinal tracts
| Groups | Parabacteroides(％) | Sutterella(％) | Akkermansia(％) | Desulfovibrio(％) |
| Chow | 1.07±0.44 | 0.70±0.25 | 3.96±0.12 | 1.43±0.35 |
| HFD | 0.22±0.05* | 0.05±0.03 | 0.03±0.02* | 2.65±0.68 |
| HFD+1.2‰D | 1.42±0.42# | 0.31±0.07# | 3.66±1.17# | 1.15±0.23 |
| HFD+1.2‰A | 1.12±0.33# | 0.02±0.01 | 1.73±0.99# | 0.74±0.16# |
| HFD+1.2‰C1 | 0.62±0.16# | 0.09±0.04 | 6.52±0.72# | 1.18±0.11# |
| HFD+1.2‰C2 | 2.71±0.15 | 0.43±0.04 | 5.86±1.66# | 0.54±0.42 |
*P<0.05,**P<0.01,compared with the chow group；#P<0.05,##P<0.01,compared with the HFD group.
Finally, it is also noted that the above list is only a few specific examples of the invention. It is obvious that the invention is not limited to the above embodiments, but many variations are possible, and all variations that can be derived or suggested by a person skilled in the art from the disclosure of the invention should be considered within the scope of protection of the invention.
Claims (5)
1. Ilicis Pubescentis saponin A1The application of the active ingredient as the only active ingredient in preparing medicines and/or health care products for treating or regulating intestinal flora disorder; wherein the intestinal flora disorder is intestinal flora disorder caused by high fat diet.
2. Ilicis Pubescentis saponin A of claim 11The application of (2), which is characterized in that: the medicine and/or health product is further added with ilexoside D, and ilexoside A1And ilexoside D in a weight ratio of 1-99: 1 to 99.
3. Ilicis Pubescentis saponin A of claim 11The application of (2), which is characterized in that: the medicine and/or the health care product is an oral preparation.
4. Ilicis Pubescentis saponin A of claim 21The application of (2), which is characterized in that: the ilexoside A1And ilexoside D in a weight ratio of 2:1 or 1: 2.
5. ilicis Pubescentis saponin A of claim 31The application of (2), which is characterized in that: the oral preparation is selected from any one of powder, oral liquid, granules, tablets, capsules or pills.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810397921.4A CN110123824B (en) | 2018-04-28 | 2018-04-28 | Ilicis Pubescentis saponin A1New use of |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810397921.4A CN110123824B (en) | 2018-04-28 | 2018-04-28 | Ilicis Pubescentis saponin A1New use of |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110123824A CN110123824A (en) | 2019-08-16 |
| CN110123824B true CN110123824B (en) | 2021-12-07 |
Family
ID=67568180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810397921.4A Active CN110123824B (en) | 2018-04-28 | 2018-04-28 | Ilicis Pubescentis saponin A1New use of |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110123824B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114939121A (en) * | 2022-04-11 | 2022-08-26 | 枣庄学院 | Application of pubescent holly root saponin A in preparation of ionizing radiation protection medicines |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284031A (en) * | 2008-06-03 | 2008-10-15 | 上海雷允上科技发展有限公司 | Hairy holly root extract, its preparation and application |
| CN102499926A (en) * | 2011-11-04 | 2012-06-20 | 刘国樵 | Application of ilexsaponin compound |
-
2018
- 2018-04-28 CN CN201810397921.4A patent/CN110123824B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284031A (en) * | 2008-06-03 | 2008-10-15 | 上海雷允上科技发展有限公司 | Hairy holly root extract, its preparation and application |
| CN102499926A (en) * | 2011-11-04 | 2012-06-20 | 刘国樵 | Application of ilexsaponin compound |
Non-Patent Citations (1)
| Title |
|---|
| Quantitative analysis of triterpenoids in different parts of Ilex hainanensis,Ilex stewardii and Ilex pubescens using HPLC–ELSD and HPLC–MSn and antibacterial activity;Xiao-Qing Chen 等;《Food Chemistry》;20101128;摘要，介绍部分 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110123824A (en) | 2019-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hong et al. | Effect of quercetin monoglycosides on oxidative stress and gut microbiota diversity in mice with dextran sodium sulphate-induced colitis | |
| Ran et al. | Sea buckthorn (Hippophae rhamnoides L.) fermentation liquid protects against alcoholic liver disease linked to regulation of liver metabolome and the abundance of gut microbiota | |
| CN108042554B (en) | Application of the ophiopogonin D on preparation treatment metabolic syndrome drug | |
| Qian et al. | Effects of lactobacillus casei YBJ02 on lipid metabolism in hyperlipidemic mice | |
| CN106103696A (en) | Novel plan lactobacillus casei bacterial strain | |
| Hou et al. | Beneficial effects of mung bean seed coat on the prevention of high-fat diet-induced obesity and the modulation of gut microbiota in mice | |
| TWI627959B (en) | Use of lactobacillus reuteri gmnl-263 for manufacturing composition for increasing expression of ldl-r and cyp7a1 in liver in high-fat diet individual | |
| CN110123824B (en) | Ilicis Pubescentis saponin A1New use of | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
| KR102158667B1 (en) | Pediococcus inopinatus WiKim0108 strain controlling immune function and ameliorating inflammatory bowel disease and use thereof | |
| Shi et al. | Effects of dietary supplementation with Radix Isatidis polysaccharide on egg quality, immune function, and intestinal health in hens | |
| CN109045070A (en) | A kind of composition for preventing and treating non-alcoholic fatty liver disease | |
| KR20160094896A (en) | The uses of hydroxyl polymethoxylflavones and/or derivative thereof | |
| CN112194595A (en) | Compound, traditional Chinese medicine probiotic fermentation product and application of compound and traditional Chinese medicine probiotic fermentation product in preparation of medicine or health-care product with cholesterol lowering effect | |
| CN114642676B (en) | Application of ginsenoside in improving intestinal flora structure and/or intestinal barrier function | |
| CN106728077B (en) | Composition with functions of regulating intestinal flora structure and preventing and treating constipation and preparation method and application thereof | |
| CN111019010B (en) | Nigella sativa seed polysaccharide, extraction method and application in preparation of medicament for treating type 2 diabetes | |
| CN111635417B (en) | Preparation method and application of tremellodon gelatinosum polyphenol for regulating intestinal flora of obese people | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
| CN111713666A (en) | Fat reducing composition and preparation method thereof | |
| CN112190644A (en) | Plant fermentation product, preparation method thereof and application of plant fermentation product in stomach health care | |
| CN110559384A (en) | Traditional Chinese medicine prebiotic composition and preparation method and application thereof | |
| CN111329928B (en) | Composition containing camellia oil and application thereof | |
| JP2021019527A (en) | Intestinal bacterial flora regulating agent | |
| WO2023000408A1 (en) | COMPOSITION COMPRISING β-NICOTINAMIDE MONONUCLEOTIDE AND ROXBURGH ROSE EXTRACT, AND APPLICATION THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |